Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) - Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes

被引：0

作者：

Hughes, B. ^{[1
]}

Mileshkin, L. ^{[2
]}

Townley, P. ^{[3
]}

Gitlitz, B. ^{[4
]}

Eaton, K. ^{[5
]}

Mitchell, P. ^{[6
]}

Hicks, R. ^{[2
]}

Loecke, D. ^{[7
]}

Amler, L. ^{[7
]}

Pirzkall, A. ^{[7
]}

机构：

[1] Royal Brisbane & Womens Hosp, Canc Care Serv, Brisbane, Qld, Australia

[2] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia

[3] Nebraska Canc Specialists, Methodist Estabrook Canc Ctr, Omaha, NE USA

[4] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[5] Univ Washington, Med Ctr, Dept Internal Med, Seattle, WA 98195 USA

[6] Austin Hosp, Ludwig Med Oncol Dept, Melbourne, Vic 3084, Australia

[7] Genentech Inc, BioOncol, San Francisco, CA 94080 USA

来源：

EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷

关键词：

D O I：

10.1016/S0959-8049(11)72431-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S629 / S629

页数：1

共 50 条

[41] A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell lung cancer (NSCLC).
Zhou, Caicun
Wang, Ziping
Sun, Meili
Cao, Lejie
Ma, Zhiyong
Wu, Rong
Yu, Yan
Yao, Wenxiu
Sun, Si
Chen, Jianhua
Zhuang, Wu
Cui, Jiuwei
Chen, Xueqin
Lu, You
Hu, Chunhong
Wang, Jingru
Chen, Rumei
Qin, Mengmeng
Wang, Hao
Yang, Jason
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
Lim, Sun Min
Cho, Byoung Chul
Han, Ji Youn
Kim, Sang We
Lee, Ki Hyeong
Nagasaka, Misako
Jo, Anna
Seah, Ethan
Kim, Choonok
Reungwetwattana, Thanyanan
CANCER RESEARCH, 2024, 84 (07)
[43] Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-TKI, in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
Lim, Sun Min
Cho, Byoung Chul
Han, Ji-Youn
Kim, Sang-We
Lee, Ki Hyeong
Nagasaka, Misako
Jo, Anna
Seah, Ethan
Kim, Choonok
Reungwetwattana, Thanyanan
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[44] Preliminary efficacy of telisotuzumab vedotin (Teliso-V) treatment in the 2L/3L setting in MET gene amplified ( MET Amp), c-Met protein overexpressing (c-Met OE), nonsquamous, non-small cell lung cancer (NSQ NSCLC): Retrospective analysis of LUMINOSITY
Camidge, D. Ross
Goldman, Jonathan
Vasilopoulos, Athan
Ansell, Peter
Xia, Summer
Bolotin, Ellen
Looman, Jim
Ratajczak, Christine
Noon, Elysa
Lu, Shun
CANCER RESEARCH, 2023, 83 (08)
[45] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): 3-year update from CheckMate 9LA
Reinmuth, Niels
Paz-Ares, Luis
Ciuleanu, Tudor-Eliade
Cobo-Dols, Manuel
Bennouna, Jaafar
Cheng, Ying
Mizutani, Hideaki
Lingua, Alejo
Reyes, Felipe
Menezes, Juliana
Jassem, Jacek
Protsenko, Svetlana
Feeney, Kynan
De la Mora Jimenez, Emmanuel
Lu, Shun
John, Thomas
Carbone, David Paul
Zhang, Xiaoqing
Hu, Nan
Reck, Martin
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 162 - 163
[46] Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC)
Van Meerbeeck, Jan P.
Cardenal, Felipe
Vansteenkiste, Johan
Stigt, Jos
Fadil, Akyol
De Neve, Wilfried
Bakker, Joke
Dupont, Jean Michel
Scagliotti, Giorgio, V
Senan, Suresh
JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S349 - S350
[47] First-line Therapy with Nivolumab (NIVO) plus Ipilimumab (IPI)+2 Cycles of Chemotherapy (chemo) vs Chemotherapy alone (4 Cycles) in Patients (pts) with metastatic non-small cell Lung Cancer (mNSCLC): 3-year Update of CheckMate 9LA
Misch, D.
Paz-Ares, L. G.
Ciuleanu, T. -E
Cobo-Dols, M.
Bennouna, J.
Cheng, Y.
Mizutani, H.
Lingua, A.
Reyes, F.
Reinmuth, N.
Menezes, J.
Jassem, J.
Protsenko, S.
Feeney, K.
Jimenez, de la Mora E.
Lu, S.
John, T.
Carbone, D. P.
Zhang, X.
Hu, N.
Reck, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 55 - 56
[48] BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents plus /- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)
Blumenschein, George
Besse, Benjamin
Gainor, Justin F.
Huang, DingZhi
Kao, Steven
Lee, Se-Hoon
Paz-Ares, Luis
Chen, Xin
He, Wanyu
Gururangan, Sridharan
Zhang, Kathy
Zhou, Caicun
CANCER RESEARCH, 2024, 84 (07)
[49] Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).
Li, Bob T.
Ahn, Myung-Ju
Goto, Koichi
Mazieres, Julien
Padda, Sukhmani Kaur
William, Nassib William
Wu, Yi-Long
Dearden, Simon
Ragone, Alejandra
Viglianti, Natasha
Gasco, Amaya
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[50] Phase 1/2 clinical trial of JIN-A02, a 4th generation EGFR-tyrosine kinase inhibitor (TKI), in patients with 3rd generation EGFR-TKI resistance in EGFR mutated advanced/metastatic non-small cell lung cancer (NSCLC)
Lim, S. M.
Cho, B. C.
Han, J. Y.
Kim, S. W.
Lee, K. H.
Nagasaka, M.
Jo, A.
Seah, E.
Kim, C.
Reungwetwattana, T.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S31 - S32

← 1 2 3 4 5 →